BMJ Open (Jun 2021)

Superiority trial comparing intraoperative wound irrigation with aqueous 10% povidone–iodine to saline for the purpose of reducing surgical site infection after elective gastrointestinal surgery: study protocol for a randomised controlled trial

  • Masaaki Saito,
  • Ryo Maemoto,
  • Hiroshi Noda,
  • Kosuke Ichida,
  • Sawako Tamaki,
  • Rina Kanemitsu,
  • Erika Machida,
  • Nozomi Kikuchi,
  • Ryotaro Sakio,
  • Hidetoshi Aizawa,
  • Taro Fukui,
  • Nao Kakizawa,
  • Yuta Muto,
  • Masahiro Iseki,
  • Rintaro Fukuda,
  • Fumiaki Watanabe,
  • Takaharu Kato,
  • Shingo Tsujinaka,
  • Yasuyuki Miyakura,
  • Toshiki Rikiyama

DOI
https://doi.org/10.1136/bmjopen-2021-051374
Journal volume & issue
Vol. 11, no. 6

Abstract

Read online

Introduction Surgical site infection (SSI) is one of the most common complications after gastrointestinal surgery, with a reported incidence of approximately 10%–25%, which is higher than the rates after other types of surgery. Intraoperative wound irrigation (IOWI) is a simple intervention for SSI prevention, and recent studies have reported that IOWI with aqueous povidone–iodine (PVP-I) is significantly more effective at reducing the incidence of SSI than saline. However, the evidence level of previous trials evaluating the efficacy of aqueous PVP-I solution for preventing SSI has been low.Methods and analyses We propose a single-institute, prospective, randomised, blinded-endpoint trial to assess the superiority of IOWI with aqueous 10% PVP-I solution compared with normal saline for reducing SSI in clean-contaminated wounds after elective gastrointestinal surgery. In the study group, IOWI with 40 mL of aqueous 10% PVP-I solution is performed for 1 min before skin suture, and in the control group, IOWI with 100 mL of saline is performed for 1 min before skin suture. We hypothesise that IOWI with aqueous 10% PVP-I solution will achieve a 50% reduction in the incidence of SSIs. The target number of cases is set at 950. The primary outcome is the incidence of incisional SSI up to postoperative day 30 and will be analysed in the modified intention-to-treat set.Ethics and dissemination This trial was designed and is being conducted by Saitama Medical Center, Jichi Medical University, with approval from the Bioethics Committee for Clinical Research, Saitama Medical Center, Jichi Medical University. Participant recruitment began in June 2019. The final results will be reported in international peer-reviewed journals immediately after trial completion.Trial registration number UMIN000036889.